Detailed Information on Publication Record
2018
Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV
SCHMIEDER, R.E., C. OTT, S.W. TOENNES, P. BRAMLAGE, M. GERTNER et. al.Basic information
Original name
Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV
Authors
SCHMIEDER, R.E. (276 Germany, guarantor), C. OTT (276 Germany), S.W. TOENNES (276 Germany), P. BRAMLAGE (276 Germany), M. GERTNER (840 United States of America), O. DAWOOD (840 United States of America), P. BAUMGART (276 Germany), B. O'BRIEN (826 United Kingdom of Great Britain and Northern Ireland), I. DASGUPTA (826 United Kingdom of Great Britain and Northern Ireland), G. NICKENIG (276 Germany), J. ORMISTON (554 New Zealand), M. SAXENA (826 United Kingdom of Great Britain and Northern Ireland), A.S.P. SHARP (826 United Kingdom of Great Britain and Northern Ireland), H. SIEVERT (276 Germany), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Zdeněk STÁREK (203 Czech Republic), J. WEIL (276 Germany), U. WENZEL (276 Germany), A. WITKOWSKI (616 Poland) and M.D. LOBO (826 United Kingdom of Great Britain and Northern Ireland)
Edition
Journal of Hypertension, PHILADELPHIA, William and Wilkins, 2018, 0263-6352
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.209
RIV identification code
RIV/00216224:14110/18:00103132
Organization unit
Faculty of Medicine
UT WoS
000429317500029
Keywords in English
renal denervation; treatment-resistant hypertension; ultrasound; WAVE IV
Tags
International impact, Reviewed
Změněno: 10/2/2019 17:22, Soňa Böhmová
Abstract
V originále
Objectives: The aim of this double-blind, randomized, sham-controlled study was to verify the blood pressure (BP)-lowering efficacy of externally delivered focused ultrasound for renal denervation (RDN). Background: Nonrandomized, first proof-of-concept study and experimental evidence suggested that noninvasive techniques of RDN emerged as an alternative approach of RDN to invasive technologies. Methods: WAVE IV, an international, randomized (1 : 1) sham-controlled, double-blind prospective clinical study, was prematurely stopped. Patients were enrolled if office BP was at least 160 mmHg and 24-h ambulatory BP was at least 135 mmHg, while taking three or more antihypertensive medications. The treatment consisted of bilateral RDN using therapeutic levels of ultrasound energy and the sham consisted of bilateral application of diagnostic levels of ultrasound energy. Results: In the 81 treated patients neither changes in office BP at 12 and 24 weeks, nor changes in 24-h ambulatory BP at 24-week follow-up visit differed between the two groups significantly. Of note, no safety signal was observed. Adherence analysis disclosed full adherence in 77% at baseline and 82% at 6 months' follow-up visit. Post hoc analysis revealed that stricter criteria for stabilization of BP at baseline were associated with a numerically greater change in 24-h ambulatory BP in the RDN group than in the sham group. Conclusion: Our data did not prove that antihypertensive efficacy of the externally delivered focused ultrasound for RDN was greater than the sham effect. Stabilization of BP at baseline was identified as an important determinant of BP changes.